Key facts
as of Sep 2026- It has raised $575.2M across 3 recorded rounds; the latest was Later Stage VC ($104.0M) in May 2024.
- Notable investors include Fidelity Management & Research Company, Qatar Investment Authority, T. Rowe Price Group, Fidelity, Durable Capital Partners — 15 tracked in total.
- 1 institutional filer reports fund marks on Kardium across 4 filings.
- Kardium has filed 3 Form Ds with the SEC since 2010, most recently Apr 2021 ($116.3M sold to 29 investors).
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$1per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Kardium
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Kardium shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest Jun 20261 SEC-registered fund reported 4 fair-value marks on Kardium between Jun 2026 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
3 roundsMay 2024Later Stage VC$104.0M▮
About Kardium
Developer of medical devices designed to help in the diagnosis and treatment of atrial fibrillation. The company's devices provide electrophysiological mapping, stimulation, and pulsed field energy to map and ablate cardiac tissue, enabling medical practitioners to diagnose and treat cardiovascular diseases with ease.
- Industry
- Diagnostic Equipment
- Sector
- Healthcare
- HQ
- Burnaby, Canada
- Founded
- 2007
- Employees
- 450
- Website
- kardium.com/
- Ownership
- Privately Held (backing)